AU2004263156B2 - Method for treating cachexia with retinoid ligands - Google Patents
Method for treating cachexia with retinoid ligands Download PDFInfo
- Publication number
- AU2004263156B2 AU2004263156B2 AU2004263156A AU2004263156A AU2004263156B2 AU 2004263156 B2 AU2004263156 B2 AU 2004263156B2 AU 2004263156 A AU2004263156 A AU 2004263156A AU 2004263156 A AU2004263156 A AU 2004263156A AU 2004263156 B2 AU2004263156 B2 AU 2004263156B2
- Authority
- AU
- Australia
- Prior art keywords
- carbons
- alkyl
- hydrogen
- lower alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49313803P | 2003-08-07 | 2003-08-07 | |
US60/493,138 | 2003-08-07 | ||
US53373403P | 2003-12-31 | 2003-12-31 | |
US60/533,734 | 2003-12-31 | ||
PCT/US2004/025564 WO2005013949A2 (fr) | 2003-08-07 | 2004-08-06 | Procédé de traitement de la cachexie au moyen de ligands de rétinoïdes |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004263156A1 AU2004263156A1 (en) | 2005-02-17 |
AU2004263156B2 true AU2004263156B2 (en) | 2009-02-26 |
Family
ID=34138739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004263156A Ceased AU2004263156B2 (en) | 2003-08-07 | 2004-08-06 | Method for treating cachexia with retinoid ligands |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1653939A2 (fr) |
JP (1) | JP2007501800A (fr) |
AU (1) | AU2004263156B2 (fr) |
CA (1) | CA2535260A1 (fr) |
WO (1) | WO2005013949A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1937244T1 (sl) | 2005-09-30 | 2018-12-31 | Io Therapeutics, Llc | Zdravljenje raka s specifičnimi RXR agonisti |
PT2056805E (pt) * | 2006-08-16 | 2011-09-02 | Action Medicines Sl | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular |
JP5902619B2 (ja) * | 2009-07-10 | 2016-04-13 | ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University | Rxrアゴニスト化合物および方法 |
EP2556827A1 (fr) * | 2011-08-11 | 2013-02-13 | Acadia Pharmaceuticals Inc. | Traitement de maladies neurodégénératives |
WO2013040227A2 (fr) | 2011-09-15 | 2013-03-21 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Composés thérapeutiques |
CA2858882C (fr) | 2011-12-13 | 2021-02-02 | Trustees Of Dartmouth College | Traitement de trouble auto-immun a l'aide d'agonistes rxr |
RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
AU2014348191B2 (en) | 2013-11-18 | 2019-03-28 | Forma Therapeutics Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
US10946001B2 (en) | 2016-03-10 | 2021-03-16 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
PL3426303T3 (pl) * | 2016-03-10 | 2022-10-03 | Io Therapeutics, Inc. | Leczenie zaburzeń mięśniowych za pomocą kombinacji agonistów rxr i hormonów tarczycy |
US10231947B2 (en) | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
US10238655B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
US10238626B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
WO2023108015A1 (fr) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Utilisation d'un agoniste de rxr dans le traitement de cancers her2+ pharmacorésistants |
AU2022408160A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist and taxanes in treating her2+ cancers |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6320074B1 (en) * | 1992-04-22 | 2001-11-20 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
CA2196197C (fr) * | 1994-08-10 | 2007-04-17 | Michael Klaus | Ligands des recepteurs x de l'acide retinoique |
IL116259A (en) * | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
-
2004
- 2004-08-06 CA CA002535260A patent/CA2535260A1/fr not_active Abandoned
- 2004-08-06 WO PCT/US2004/025564 patent/WO2005013949A2/fr active Application Filing
- 2004-08-06 EP EP04780406A patent/EP1653939A2/fr not_active Withdrawn
- 2004-08-06 AU AU2004263156A patent/AU2004263156B2/en not_active Ceased
- 2004-08-06 JP JP2006522776A patent/JP2007501800A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
Non-Patent Citations (1)
Title |
---|
V. Vuligonda et al J Med Chem 2001 Vol 44 No 14 page 2298 - 2803. * |
Also Published As
Publication number | Publication date |
---|---|
WO2005013949A2 (fr) | 2005-02-17 |
EP1653939A2 (fr) | 2006-05-10 |
WO2005013949A3 (fr) | 2005-09-15 |
AU2004263156A1 (en) | 2005-02-17 |
JP2007501800A (ja) | 2007-02-01 |
CA2535260A1 (fr) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070185055A1 (en) | Method for treating cachexia with retinoid ligands | |
AU2004263156B2 (en) | Method for treating cachexia with retinoid ligands | |
US5811449A (en) | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases | |
US6794396B2 (en) | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity | |
AU2003277162B2 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
JP5927236B2 (ja) | 乾癬を予防または低減する方法 | |
WO2008091338A1 (fr) | Procédés et compositions destinés au traitement de la résistance à l'insuline, du diabète et d'une dyslipidémie associée au diabète | |
KR20210151816A (ko) | 칸나비노이드 산 에스테르 조성물 및 이의 용도 | |
CA2839727C (fr) | Systemes, methodes, et formulations pour traiter le cancer | |
AU2017291211A1 (en) | Methods for inhibiting conversion of choline to trimethylamine (TMA) | |
US20030212074A1 (en) | Phosphate transport inhibitors | |
CA2911902A1 (fr) | Formulations pharmaceutiques d'attenuation de rayonnements | |
RU2011108587A (ru) | Новые метилендиоксифенольные соединения и их применение для лечения заболеваний | |
WO2009016081A2 (fr) | Composés destinés à être utilisés en thérapie | |
JPH10511978A (ja) | アルツハイマー病の治療用薬剤 | |
CH631713A5 (fr) | Derives de chromones a activite medicamenteuse et leur preparation. | |
WO2005037759A1 (fr) | Nouveau derive de phenol et agent preventif/therapeutique anti-trypanosome le contenant comme principe actif | |
AU709939B2 (en) | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases | |
AU733198B2 (en) | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases | |
JPS62198616A (ja) | 脳血流量改善・脳細胞保護剤 | |
JP2021024826A (ja) | 糖化産物生成抑制剤及び医薬組成物 | |
WO2023235326A1 (fr) | Compositions et méthodes de traitement de porphyries hépatiques avec des inhibiteurs de transport de glycine | |
RU2588133C2 (ru) | Ниациновые миметики и способ их использования | |
WO2017175859A1 (fr) | Médicament pour prévenir ou traiter l'acidose lactique | |
US20090281159A1 (en) | Use of hdac inhibitors for the treatment of lymphomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |